Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

January 2, 2019

Study Completion Date

January 2, 2019

Conditions
Genitourinary CancerKidney Cancer
Interventions
DRUG

Sunitinib

"Starting dose: 50 mg by mouth daily given for 2 weeks on followed by 1 week off. 1 cycle is 6 weeks."

BEHAVIORAL

Questionnaire

Questionnaire completion on Day 1 of Cycle 1, and on Day 35 of Cycles 2, 4, and 6.

Trial Locations (5)

27514

Lineberger Cancer Center, Chapel Hill

44195

Cleveland Clinic Taussig Cancer Institute, Cleveland

77030

University of Texas MD Anderson Cancer Center, Houston

94305

Stanford University Medical Center, Stanford

19111-2497

Fox Chase Cancer Center, Philadelphia

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT02060370 - Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC) | Biotech Hunter | Biotech Hunter